Compare BCRX & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCRX | BHC |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1995 | 1996 |
| Metric | BCRX | BHC |
|---|---|---|
| Price | $9.55 | $4.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 3 |
| Target Price | ★ $20.82 | $8.00 |
| AVG Volume (30 Days) | ★ 5.5M | 2.8M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 381.40 | ★ 423.08 |
| EPS | ★ N/A | N/A |
| Revenue | $25,186,000.00 | ★ $8,724,000,000.00 |
| Revenue This Year | N/A | $4.61 |
| Revenue Next Year | $12.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.00 | $4.57 |
| 52 Week High | $10.94 | $8.69 |
| Indicator | BCRX | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 43.20 |
| Support Level | $8.04 | $4.57 |
| Resistance Level | $10.04 | $6.31 |
| Average True Range (ATR) | 0.49 | 0.28 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 50.88 | 20.29 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.